A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma



Status:Recruiting
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:11/18/2012
Start Date:December 2009
Contact:Elisabeth Sonesson, PhD
Email:elisabeth.sonesson@bioinvent.com
Phone:+46462868550

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI 505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, in Patients With Relapsed/Refractory Multiple Myeloma


This is a first in human study which will assess the safety and tolerability of a monoclonal
antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will
also be measured.


Inclusion Criteria:

- Advanced Myeloma with measurable disease after at least 2 previous regimens.

- Life expectancy > 3 months.

- Performance status ECOG < 2.

Exclusion Criteria:

- Prior antineoplastic therapy within 4 weeks prior to inclusion.

- No high dose steroids within 7 days prior to screening.

- Severe other conditions.
We found this trial at
2
sites
University of Utah Health Sciences Center, Department of Medicine, Division of Hematology, Utah Blood and Marrow Transplant and Myeloma Program
Salt Lake City, Utah 84132
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
University of Maryland Greenebaum Cancer Center
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials